A real world, cohort study to investigate outcomes of once weekly Long -Acting GLP -1 Receptor Agonist Treatment in patients with Type 2 Diabetes Mellitus

Trial Profile

A real world, cohort study to investigate outcomes of once weekly Long -Acting GLP -1 Receptor Agonist Treatment in patients with Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Albiglutide (Primary) ; Dulaglutide (Primary) ; Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2017 Results (n=2465) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Results (n=760) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 24 May 2017 Results presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top